Jersey is a Crown Dependency. It is not in the EU, has never been in the EU, and does not automatically inherit EU law. It sits outside the UK's NHS-shaped clinical framework and legislates its own health and medicines rules through the States Assembly. Where the UK and EU converge on cautious defaults — often for defensible historical reasons that no longer bind Jersey — the island can consciously adopt a different position.
Jersey has already shown it will use this freedom. In February 2026 the States Assembly adopted the Assisted Dying (Jersey) Law, which went on to receive Royal Assent — making Jersey the first jurisdiction in the British Isles to legalise assisted dying, while the UK's own Terminally Ill Adults (End of Life) Bill was defeated in the House of Commons in September 2026. The law is for Jersey residents only, by design, so it is not one of the domains below. But it is the clearest proof that Jersey can write its own health regulation on a contested question, carefully, and see it through.
This page is written for a mixed audience: politicians, policy officials, biotech partners, and clinicians. Each domain below opens with a plain-English explanation of the medicine or science, so no medical background is required. Every domain then covers current UK / EU / global regulatory position, published peer-reviewed evidence of clinical value (with clickable links to the primary papers), the addressable market with sourced projections, and specific Jersey economic impact if the framework is implemented. Aggregate economic impact across all seven domains, adjacent-industry multipliers, and the medical-IP structuring opportunity for Jersey's funds services industry is set out on the separate Economic Impact page.
All market figures are directional 2024-2030 projections drawn from published market-research firms and government statistics; every source is cited inline. Jersey-specific revenue estimates are illustrative — they combine the market data with reasonable assumptions about the share Jersey could capture given its size, geography, and regulatory positioning.
Not on cost. On certainty.
Jersey will not win on price. Clinical work is cheaper almost everywhere else, and Jersey has a small population to recruit from. Australia already offers fast early-phase trial approvals, generous research tax rebates and, since 2023, authorised prescribing of psilocybin and MDMA. Being faster than the UK is not enough on its own. Jersey's advantage has to come from a narrow set of things that matter more than price:
- A published route from research to authorised treatment. Jersey would set out in advance the evidence it needs — for example, strong Phase 2 results plus registry safety data — before a treatment can be authorised on the island. A sponsor whose research succeeds then has a real, if small, market straight away. Most of the income comes from authorised treatment afterwards; research is the entry point. No major regulator offers this today.
- Bespoke medicines for rare diseases. For one-patient (n=1) medicines, speed and certainty matter far more than cost, and families and charities often fund the work. A small but real niche.
- Research the UK makes slow. In the UK, research with controlled drugs such as psilocybin needs a Home Office licence that takes months. Jersey has its own drugs law and could make research licensing faster — though Australia and the Netherlands already offer similar access.
- Longevity funders. Well-funded longevity philanthropies and biotechs want a credible regulator prepared to assess treatments against biological-ageing markers, which no major regulator yet accepts as a basis for approval. A rigorous Jersey framework could attract them.
- Capital and venue together. Jersey's funds industry could finance research run on the island, with medical-IP structuring alongside (see Economic Impact).
The same features could attract the wrong partners: sponsors that regulators elsewhere have turned away. Jersey's offer must be the same evidence bar applied faster — never a lower one. The political case sets out why this is the opposite of a regulation-free zone.
Reproductive medicine.
Reproductive medicine is the branch of medicine that helps people conceive, or helps them conceive on terms they can choose. The core technology is IVF (in-vitro fertilisation): eggs are collected from the mother, fertilised with sperm in a laboratory, developed to an early embryo stage, and one or more embryos are transferred back to the mother's uterus. Around the world roughly 3.5 million IVF cycles are now performed each year, a figure that has doubled in the last decade (International Federation of Fertility Societies, 2023).
IVF as a platform enables several separate services: choosing which of several viable embryos to transfer (embryo selection), screening embryos for genetic conditions before transfer (preimplantation genetic testing), preserving eggs or embryos for later use (fertility preservation), and correcting inherited mitochondrial disease (mitochondrial replacement therapy). Different countries permit different subsets of these services under different conditions. The UK's regulator, the Human Fertilisation and Embryology Authority (HFEA), takes a comparatively cautious position that leaves several defensible services either forbidden or delivered at very limited scale.
1a · Sex-selection IVF for family balancing
Standard IVF where, before an embryo is transferred to the mother, its chromosomes are analysed to determine sex (XX for female, XY for male). Prospective parents then choose which embryo to transfer. Technically straightforward — the same biopsy used for other genetic testing — but used for a non-medical purpose: families balancing sex ratio, or cultural preference.
Under UK / EU today
In the UK, the Human Fertilisation and Embryology Act 1990 (§13(9)) forbids sex selection for non-medical reasons. It is permitted only where sex is linked to a serious genetic disease (for example, haemophilia is X-linked). Sex-selection IVF is openly practised in the US, Cyprus, Mexico, and Thailand. Israel permits it under case-by-case medical and ethical review. An estimated 1,000-1,500 UK couples per year travel abroad specifically for sex selection at typical all-in cost of £15,000-30,000 per cycle including travel and accommodation — £15-45 million in UK household spending currently flowing offshore, plus a comparable and larger European flow to the same destinations.
- Reinforces preference for one sex over the other, which regulators and the public have treated as discriminatory in principle.
- Where sex selection is widespread it has distorted population sex ratios, the main reason many countries ban it outright.
- Puts otherwise fertile couples through IVF — hormone stimulation, egg collection, risk of ovarian hyperstimulation syndrome — for a non-medical reason.
- Seen as a first step towards selecting children for non-medical traits. The Council of Europe’s Oviedo Convention prohibits it except to avoid serious sex-linked disease.
- When the UK regulator consulted the public, a large majority opposed allowing it.
What this means for Jersey. The objections are ethical rather than clinical. Jersey would need to decide it disagrees with them, not just manage them — and should expect this to be the most contested item in the framework.
Under a Jersey framework
An authorised sex-selection IVF pathway with mandatory pre-cycle counselling (typically two sessions with a fertility counsellor covering psychological, ethical, and family-dynamic considerations), family-balancing gatekeeping criteria (e.g., minimum one existing child of the opposite sex for the family-balancing indication) to prevent misuse, quality standards for authorised IVF providers, and outcome-registry participation. Not the US "pay-and-select" model — a considered pathway with counselling built in as a condition of access.
In practice
A UK couple with three sons who want a daughter for family balancing could access a Jersey clinic under proper counselling and quality standards — currently they fly to Cyprus or Los Angeles at £15-30k plus travel and hotel. A Jersey resident couple can access the same service without leaving the island. The framework captures the value that currently flows offshore while ensuring the ethical scaffolding the destination markets often lack.
1b · Egg and embryo freezing (fertility preservation)
Eggs (or fertilised embryos) are collected from a woman in her 20s or 30s, frozen using vitrification (an ultra-fast freezing technique that avoids ice damage), and stored for potential later use. Egg quality declines materially from a woman's mid-30s onward; freezing eggs earlier preserves the biological option to have children later, whether for medical reasons (chemotherapy about to begin), professional reasons (career priorities), or simply because a life partner has not yet arrived.
Under UK / EU today
The UK now permits eggs and embryos to be stored for up to 55 years under the Human Fertilisation and Embryology (Statutory Storage Period for Embryos and Gametes) Regulations 2022 — up from the previous 10-year cap, which had forced many women to discard viable eggs. Access is legal but expensive (£4,000-8,000 per collection cycle plus £300-500 per year of storage) and quality varies considerably between private clinics. HFEA reports egg-freezing cycles have grown at 30-40% CAGR over the last five years (roughly 1,500 cycles in 2018 to over 4,200 in 2022). Comprehensive fertility-preservation programmes combining assessment, collection, and long-term storage under a single quality standard are rare.
- Success rates fall sharply with age at freezing; marketing can overstate the chance of a later baby.
- Most women who freeze eggs never return to use them, so many pay for a service they do not use.
- Egg collection carries the usual IVF risks, including ovarian hyperstimulation syndrome.
- Can create false reassurance and lead people to delay trying to conceive.
What this means for Jersey. Already legal and regulated in the UK. The priority is honest, age-specific success-rate information and proper counselling — not looser rules.
Under a Jersey framework
Higher-service elective preservation offering: comprehensive fertility assessment (ovarian reserve testing, AMH, antral follicle count, tubal patency), full genetic screening (carrier status; PGT-A of any frozen embryos), integration with longevity-programme baseline (biological-age markers, metabolic assessment, hormonal profile), long-term storage at a Jersey facility with UK-equivalent regulatory framework, and full price + quality transparency. Storage indefinite under Jersey framework rather than the UK's 55-year cap.
In practice
A woman in her early 30s planning fertility preservation could complete a full assessment plus collection cycle at a licensed Jersey fertility centre, with results integrated into a wider longevity baseline. A patient returning annually could receive updated assessments against her stored eggs' provenance. The preservation is not a stand-alone commercial service but part of a wider longevity + fertility programme.
1c · Mitochondrial replacement therapy (MRT)
Every human cell contains two separate sets of genetic material. The nuclear DNA — the large genome of roughly 20,000 genes — sits inside the cell nucleus and determines almost everything commonly thought of as inherited: appearance, most personality traits, disease predispositions. A much smaller, second set of genetic material sits inside the mitochondria, the cell's energy-producing organelles. This mitochondrial DNA (mtDNA) contains only 37 genes, and it is inherited exclusively from the mother.
When a woman's mtDNA carries a disease-causing mutation, she risks passing mitochondrial disease to her children. Mitochondrial diseases range from mild fatigue to lethal childhood conditions such as Leigh syndrome, and they typically affect the most energy-hungry tissues — brain, heart, muscle. Roughly one in every 4,300 people carries a disease-causing mtDNA mutation (Nuffield Council on Bioethics, 2012). Once a child is born with mitochondrial disease, there is no cure.
MRT prevents transmission by separating the two genomes. The mother's egg (or her fertilised zygote) is emptied of its nuclear DNA — the mother's actual "genome" in the everyday sense — which is then transferred into a donor egg that has been emptied of its own nuclear DNA but retains its healthy mitochondria. The result: an egg (or zygote) with the intended parents' nuclear DNA and the donor's healthy mitochondrial DNA. Casually called "three-parent IVF," but roughly 99.9% of the resulting child's DNA is from the intended parents — the mitochondrial contribution is 37 genes out of over 20,000.
Under UK / EU today
The UK became the world's first country to specifically legislate for MRT in 2015, following a decade of ethical review including a full Nuffield Council report and a public consultation. However, delivery is bottlenecked at a single centre — the Newcastle Fertility Centre — with HFEA case-by-case authorisation for each treatment. The first UK MRT baby was announced in May 2023, eight years after legalisation, at which point only around 30 women had received treatment. The US has no FDA-approved pathway and MRT is effectively forbidden; most of Europe forbids it; a handful of Ukrainian and Greek clinics offer it privately with variable quality. UK adult carriers of disease-causing mtDNA mutations number roughly 15,000; US + European carriers together number over 500,000. Even at very low engagement rates (0.5-1%) the addressable global cohort is 2,500-5,000 women per year — orders of magnitude beyond current UK capacity.
- Changes are inherited by future generations, which is why the EU prohibits trials that alter the germline and the US has barred its regulator from reviewing such applications.
- Small amounts of faulty mitochondrial DNA can carry over and, in some reported cases, increase again after treatment.
- Long-term health effects on children, and on their own children, are not yet known.
- Raises questions about identity and parentage (often described as “three-parent babies”).
What this means for Jersey. The UK permits it only case by case at one licensed centre, with long-term follow-up. Jersey should not go further than the UK’s safeguards; any service should mirror them.
Under a Jersey framework
Additional authorised MRT centres in Jersey operating under an extended version of the UK's existing legal framework — no new ethics work required, Nuffield and Parliament have already done the underlying work. Case-by-case authorisation with the same rigour as Newcastle but with capacity for materially more cycles per year. Coordination with UK and international mtDNA-carrier registries to expand the reachable patient population. Mandatory outcome-registry participation adds long-term safety data across a larger cohort than a single UK centre can generate.
In practice
A UK woman carrying a Leigh-syndrome mtDNA mutation currently on the Newcastle waiting list could complete MRT in Jersey within months rather than years. Her family remains close (short flight from any UK city); the clinical governance matches UK standards because the same legal framework applies; her contribution to outcome data accelerates safety knowledge across the field. US and EU patients otherwise flying to Ukraine or Greece for variable-quality delivery gain access to a UK-standard framework in a considerably nearer location.
1d · Preimplantation genetic testing — polygenic (PGT-P)
Preimplantation genetic testing (PGT) is the practice of analysing an embryo's DNA during an IVF cycle before transferring it to the mother. Standard IVF produces multiple viable embryos; PGT allows prospective parents to select which embryo(s) to transfer based on genetic information. There are three types with very different levels of scientific and ethical maturity:
- PGT-M (monogenic) screens for known single-gene disorders where both parents are carriers — cystic fibrosis, Huntington's, BRCA1/2, Tay-Sachs, sickle cell. Mainstream for two decades.
- PGT-A (aneuploidy) screens for chromosomal abnormalities — Down syndrome, other trisomies, most first-trimester miscarriages. Permitted; adoption varies.
- PGT-P (polygenic) is the newest and most contested type. Instead of looking for one specific gene, PGT-P sequences the embryo's whole genome and calculates polygenic risk scores — statistical predictions of the embryo's genetic likelihood of many conditions at once. Prospective parents can then compare embryos across a menu of risk profiles for coronary artery disease, type 2 diabetes, several cancers, inflammatory bowel disease, Alzheimer's, schizophrenia, and bipolar disorder. Some US providers also offer cognitive-trait scores — the most ethically contested corner of the field.
Under UK / EU today
PGT-M and PGT-A are permitted in the UK for HFEA-approved conditions. PGT-P is essentially unavailable in the UK and EU — the HFEA has not authorised polygenic risk scoring for embryo selection, no licensed UK provider offers it, and UK couples who want it fly to the US. In the US, PGT-P sits in a regulatory vacuum: the FDA does not approve genetic tests used in embryo selection, providers self-govern (Orchid Health, Genomic Prediction, Nucleus Genomics), and clinical governance varies dramatically. Prices: $10,000-25,000 per cycle on top of the ~$20,000 base cost of IVF. Market is growing at 40%+ CAGR (Grand View Research projects global PGT market to $2.3B by 2030, with polygenic the fastest-growing subsegment).
- The expected benefit is small: choosing between a handful of sibling embryos shifts disease risk by only modest amounts.
- Scores are built mainly from people of European ancestry and are much less accurate for others.
- Genes affect many traits at once, so selecting against one condition can raise the risk of another.
- Leading bodies, including the European Society of Human Genetics, say it is unproven and not ready for clinical use; the UK does not permit it.
- Risks misleading marketing to parents, and a drift towards selecting for non-medical traits.
What this means for Jersey. The evidence does not currently support offering this as a service. If Jersey pursues it at all, it should be as a research programme with independent ethics oversight, not a paid clinical product.
Under a Jersey framework
A research-first approach. Rather than licensing PGT-P as a clinical service, Jersey would host a regulated research programme under independent ethics oversight. Mandatory pre-conception counselling (two sessions with a genetics counsellor covering the statistical nature of polygenic scores, how small the expected benefit is, and the ethical territory). Scoring restricted to serious disease risk (coronary artery disease, type 2 diabetes, defined cancers, Alzheimer's) — cognitive-trait and physical-trait scoring explicitly excluded. Technical standards for score calculation (calibration, ancestry-specific accuracy, uncertainty quantification). Full outcome follow-up. Any move from research to a clinical service would depend on the programme's results and independent review.
In practice
A couple with a strong family history of early-onset Alzheimer's on both sides could take part in the Jersey research programme during standard IVF, with full counselling on how modest and uncertain the benefit is. Today the service exists in the US with weak oversight and is unavailable in the UK. Jersey's contribution would be the evidence the field currently lacks — not another commercial offer.
- Craven L, et al. (2010). "Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease." Nature 465:82-85. doi.org/10.1038/nature08958
- Turley P, et al. (2021). "Problems with using polygenic scores to select embryos." New England Journal of Medicine 385:78-86. doi.org/10.1056/NEJMsr2105065
- Karavani E, et al. (2019). "Screening human embryos for polygenic traits has limited utility." Cell 179:1424-1435. doi.org/10.1016/j.cell.2019.10.033
- Cobo A, et al. (2016). "Oocyte vitrification as an efficient option for elective fertility preservation." Fertility & Sterility 105:755-764. doi.org/10.1016/j.fertnstert.2015.11.027
- Nuffield Council on Bioethics (2012). "Novel techniques for the prevention of mitochondrial DNA disorders: an ethical review." nuffieldbioethics.org
- Global fertility services market
- $41B in 2024, projected $65B by 2030 (Grand View Research, IVF Services Market 2024)
- Global preimplantation genetic testing
- $700M in 2023, projected $2.3B by 2030 (Grand View Research, PGT Market 2024)
- Global fertility preservation
- $3.6B in 2023, projected $8.4B by 2030 (Precedence Research, 2024)
- UK addressable inbound
- ~£150-450M/year at maturity across sex selection, MRT and PGT-P combined
- European addressable inbound
- ~€1-2.5B/year at maturity if Jersey is the first properly-regulated European jurisdiction
- Jersey direct revenue at maturity
- £85-225M/year (revised: PGT-P moves to research; sex selection, fertility preservation and MRT remain services; includes £1-5M sponsor-funded research income)
- Adjacent-industry multiplier (hospitality, professional services, real estate)
- £35-90M/year
- Total Jersey economic contribution — reproductive medicine
- £120-315M/year
What Jersey could offer in reproductive medicine
A modern, ethically-scaffolded reproductive-medicine framework covering sex selection with counselling, extended fertility-preservation services, and MRT at additional accredited centres (using the existing UK legal basis and safeguards). For PGT-P, a research programme under independent ethics oversight rather than a clinical service — building the evidence the field currently lacks. Positioned as the considered, transparent regulator: mandatory counselling, disease-risk scoring only, quality standards, and full outcome follow-up. The reference standard, not the wild west.
Psychedelic therapeutics.
Psychedelic-assisted therapy uses controlled doses of psychedelic substances — psilocybin (the active ingredient in "magic mushrooms"), MDMA (also known as ecstasy), ketamine, and ibogaine — administered by trained therapists in structured therapeutic sessions to treat mental-health conditions. It is not the recreational use these substances are more commonly associated with: doses are calibrated, sessions are supervised, integration therapy follows over subsequent weeks, and screening excludes patients where the substance carries specific risks (personal or family history of psychosis, certain cardiac conditions).
The clinical evidence has grown substantially over the last decade, but it is not yet settled. Randomised controlled trials of psilocybin-assisted therapy have shown rapid improvement in treatment-resistant depression for some patients, though response rates vary, the trials are small, and how long the benefit lasts is unclear. MDMA-assisted therapy for post-traumatic stress disorder produced strong Phase 3 results — two-thirds of participants no longer met PTSD diagnostic criteria after treatment — but the FDA declined approval in 2024 over concerns about blinding, safety data and trial conduct. Ketamine, already legal, is now widely used off-label for severe depression, with rapid but often short-lived effects.
Current position. Australia rescheduled psilocybin and MDMA in July 2023 to permit prescribed therapeutic use by authorised psychiatrists. The US FDA granted breakthrough-therapy designation to both substances, but in August 2024 it declined to approve MDMA-assisted therapy for PTSD and asked for a further Phase 3 trial. The UK remains stuck at Schedule 1 for psilocybin and MDMA — meaning they have no recognised medical use — and any research requires a cumbersome Home Office licence.
Consequence. There is no legal psychedelic-assisted therapy market in the UK. Patients seek treatment through legally-grey routes in the Netherlands (where psilocybin truffles remain legal), Jamaica, and Portugal, or through UK ketamine clinics that operate under existing licensing. Substantial unmet demand exists among an estimated 2 million UK adults with treatment-resistant depression (NHS estimates) and a further 1.5 million with PTSD (King's College London, 2023).
2a · Psilocybin-assisted therapy
The most-advanced-evidence psychedelic-assisted therapy indication. Used for treatment-resistant depression (patients who have failed two or more antidepressants), end-of-life distress in terminal cancer patients, obsessive-compulsive disorder, and alcohol / tobacco use disorders. Typical protocol: two supervised dosing sessions with sustained benefit; some patients receive follow-up sessions after 3-12 months.
Under UK / EU today
Psilocybin remains at Schedule 1 in the UK under the Misuse of Drugs Regulations 2001 — meaning no recognised medical use. Research access requires a Home Office licence (approximately £3,000, several months to obtain). No UK psychiatrist can prescribe psilocybin therapeutically. UK patients with treatment-resistant depression seeking psilocybin therapy access it through legally-grey routes in the Netherlands (psilocybin truffles remain legal), Jamaica, or Portugal — without proper clinical governance or integration follow-through.
- Can trigger severe anxiety, and psychosis in people with a personal or family history; screening is essential.
- Trials have reported suicidal thoughts and behaviour in some participants.
- Hard to run as a blinded trial — most participants can tell whether they had the drug — so benefits may be overstated.
- Trials so far are small and short; how long benefits last is unclear.
- Patients are highly vulnerable during sessions; there have been cases of therapist misconduct in psychedelic research.
What this means for Jersey. Evidence is promising but incomplete. Jersey should start inside research protocols, with psychiatric screening, two-therapist sessions and outcome registration.
Under a Jersey framework
Phased. First, psilocybin-assisted therapy delivered inside ethics-approved research protocols, with licensing simplified for approved research. Psychiatrists plus trained co-therapists (two therapists present during every dosing session), mandatory screening (cardiac and psychiatric contraindications; personal or family history of psychosis ruled out), supervised session protocols, integration therapy over 4-8 weeks after dosing, suicide-risk monitoring, and mandatory outcome registration. A licensed-practitioner framework — modelled on Australia's authorised-prescriber scheme — would follow only if research and registry data support it.
In practice
A patient with treatment-resistant depression who has not responded to several antidepressants and talking therapy could take part in a Jersey research programme — a proper clinical protocol under psychiatrist supervision rather than an unregulated retreat. Phase 2 trials have shown rapid improvement for some patients, but response rates vary, the trials are small, and how long the benefit lasts is not yet known.
2b · MDMA-assisted therapy
MDMA-assisted therapy is used specifically for post-traumatic stress disorder. In clinical protocols, patients receive 2-3 MDMA-assisted sessions across 8-12 weeks, each session lasting a full day, with two therapists present. Between sessions there are integration therapy sessions to consolidate the therapeutic work.
Under UK / EU today
MDMA at Schedule 1 in the UK (same status as psilocybin). Research access via slow Home Office licence process. No route for therapeutic use. The FDA granted MDMA-assisted therapy breakthrough-therapy designation, but declined to approve it in August 2024, citing concerns about the trial evidence and asking for a further Phase 3 study. Australia has rescheduled MDMA to permit prescribed therapeutic use. The UK MHRA pathway is not on the horizon; UK veterans with treatment-resistant PTSD have essentially no legal domestic option.
- The FDA declined approval in August 2024 after its advisory committee voted that effectiveness was not shown and that benefits did not outweigh risks.
- Most trial participants could tell they had received MDMA, so expectation may explain part of the effect.
- Safety data were incomplete; reviewers said effects such as euphoria and abuse potential were not properly recorded.
- Raises heart rate and blood pressure, with some risk to the heart and liver.
- A documented case of therapist sexual misconduct in an earlier trial raised concerns about conduct and oversight.
What this means for Jersey. Not ready for routine use. Research only, under strict therapist standards and independent monitoring.
Under a Jersey framework
Research only, for now. MDMA-assisted therapy for post-traumatic stress disorder offered inside ethics-approved trials designed to answer the FDA's concerns: better blinding strategies, systematic recording of adverse effects and abuse potential, independent safety monitoring, two therapists present at every session, recorded sessions and clear conduct safeguards. Mandatory long-term follow-up. Wider availability would follow only if those trials succeed.
In practice
A veteran with treatment-resistant PTSD could enrol in a Jersey trial with full safety monitoring. The earlier Phase 3 results were encouraging — two-thirds of participants no longer met PTSD diagnostic criteria after treatment — but FDA reviewers questioned how robust those trials were. Settling that question properly is what Jersey's trials would be for.
2c · Ketamine and ibogaine
Ketamine is an anaesthetic dissociative already used off-label for severe depression with rapid onset. Ibogaine is an alkaloid derived from West African iboga root that shows promise for opioid use disorder — single-dose administration can eliminate withdrawal symptoms and cravings — but carries cardiac risks that require careful screening.
Under UK / EU today
Ketamine is legal in the UK for depression under private prescription. Approximately 30 UK clinics operate ketamine treatment for depression — with wide variation in dosing protocols, patient selection, and integration support. No unified framework or quality standard. Ibogaine at Schedule 1 in the US, unscheduled in many jurisdictions, carries a specific cardiac risk (QT-interval prolongation, arrhythmia). Not available in the UK under any legal framework; UK patients with opioid use disorder seeking ibogaine treatment travel to Mexico or the Caribbean, often to clinics with weak or absent cardiac screening.
- Ibogaine can cause dangerous heart-rhythm changes; deaths have been documented in treatment settings, and there are no large controlled trials.
- Ibogaine is metabolised very differently from person to person and interacts dangerously with opioids — the very patients it is offered to.
- Ketamine raises blood pressure, causes dissociation, and carries a risk of dependence.
- Frequent ketamine use can cause serious bladder damage.
- Ketamine’s antidepressant effect is often short-lived, so patients need repeated doses. NICE did not recommend the licensed esketamine spray for the NHS, citing uncertain benefit and cost.
What this means for Jersey. Ketamine can be offered under tight protocols. Ibogaine should be excluded from treatment and considered, if at all, only as hospital-based research with cardiac monitoring.
Under a Jersey framework
Ketamine treatment formalised with quality-standard requirements: standardised dosing protocols, blood-pressure monitoring, therapist support during dosing, integration therapy, screening for dependence and bladder symptoms, and mandatory outcome tracking. A regulated standard the private market can align to. Ibogaine is excluded from treatment: at most, Jersey could host hospital-based research with continuous cardiac monitoring, if a credible research partner proposed it.
In practice
A patient with treatment-resistant depression could access a properly regulated ketamine protocol at a licensed Jersey clinic, with safety monitoring built in. Ibogaine would not be offered as treatment; patients with opioid use disorder would continue to receive established treatments such as buprenorphine and methadone.
- Carhart-Harris R, et al. (2021). "Trial of Psilocybin versus Escitalopram for Depression." New England Journal of Medicine 384:1402-1411. doi.org/10.1056/NEJMoa2032994
- Mitchell JM, et al. (2021). "MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study." Nature Medicine 27:1025-1033. doi.org/10.1038/s41591-021-01336-3
- Ross S, et al. (2016). "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer." Journal of Psychopharmacology 30:1165-1180. doi.org/10.1177/0269881116675512
- Bogenschutz MP, et al. (2022). "Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in Adults with Alcohol Use Disorder." JAMA Psychiatry 79:953-962. doi.org/10.1001/jamapsychiatry.2022.2096
- Zarate CA, et al. (2006). "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression." Archives of General Psychiatry 63:856-864. doi.org/10.1001/archpsyc.63.8.856
- Global psychedelic therapy market
- $4.9B in 2024, projected $11.8B by 2029 (Data Bridge Market Research, 2024)
- Alternative projection
- $3.2B in 2023 projected $8.3B by 2029 (Precedence Research, 2024)
- UK addressable
- ~£175-500M/year at maturity given prevalence + treatment cost per patient
- European addressable
- ~€2-5B/year at maturity given comparable disease burden across the EU
- Jersey direct revenue at maturity
- £30-110M/year (revised: psilocybin and MDMA move to research; ibogaine excluded; ketamine remains a service; includes £2-10M sponsor-funded research income)
- Adjacent-industry multiplier
- £10-35M/year
- Total Jersey economic contribution — psychedelic therapeutics
- £40-145M/year
What Jersey could offer in psychedelic therapeutics
A staged framework for psychedelic-assisted therapy: ketamine under formal quality standards; psilocybin and MDMA inside ethics-approved research programmes first, with training standards, two-therapist sessions, cardiac and psychiatric screening, integration support and mandatory outcome registration; ibogaine excluded from treatment. Positioned alongside — not against — traditional mental-health services. With the FDA's 2024 rejection of MDMA-assisted therapy and MHRA inertia, Jersey has an open window to be the first European jurisdiction with proper clinical governance — starting with research that builds the evidence regulators have asked for.
Cannabis therapeutics.
Cannabis-based medicine covers a spectrum of products: full-spectrum extracts, isolated cannabidiol (CBD) for epilepsy, tetrahydrocannabinol (THC) for pain and appetite, and specialty formulations for specific indications. The medical evidence base is now robust for several indications — nausea and appetite in cancer chemotherapy patients, refractory paediatric epilepsy, chronic neuropathic pain, and multiple sclerosis spasticity — while remaining more contested for anxiety, sleep, and psychiatric applications.
Jersey has already moved decisively on the cultivation side. The Misuse of Drugs (Cannabis Licensing) (Jersey) Order 2020 permitted domestic medicinal cannabis cultivation, and licensed operations are now producing pharmaceutical-grade cannabis on the island. This puts Jersey in an unusual position: upstream capacity is in place, but the downstream regulatory framework governing patient access still mirrors the UK's slow prescription pathway.
3a · Prescriber pathway and formulary access
Who can prescribe medicinal cannabis, for what indications, and with what product range — the three levers that determine how much of a real cannabis-medicine market can exist inside a legal framework.
Under UK / EU today
In the UK, medicinal cannabis has been legally prescribable since November 2018 but only by consultants on the Specialist Register, only for specific approved indications, and only after two prior conventional treatments have failed. The result is a very small legal patient base (~40,000-60,000 UK patients as of 2024) despite a much larger clinical demand — an estimated 1.4 million UK adults use cannabis medicinally, most of them illegally (Centre for Medicinal Cannabis, 2023). The MHRA formulary is narrow, favouring pharmaceutical-brand cannabinoid products (Sativex, Epidiolex) over full-spectrum extracts.
- NICE found insufficient evidence to recommend cannabis medicines for most conditions, including chronic pain.
- High-THC products raise the risk of psychosis, especially in young people and those with a family history.
- Can cause dependence, affect memory and concentration, and impair driving.
- Interacts with other medicines, including some epilepsy treatments.
- UK regulators have raised concerns about high-volume prescribing by some private clinics.
What this means for Jersey. Wider access should come with specialist oversight, THC limits for younger patients, driving advice and outcome data — not simply more prescribers.
Under a Jersey framework
Prescriber pathway broadened beyond the UK Specialist Register requirement to include GPs with cannabis-medicine training, allowing primary-care prescribing for defined chronic-pain, oncology, and neurological indications with proper training and monitoring. Formulary breadth authorising products the UK MHRA has not approved: full-spectrum extracts, novel cannabinoid formulations, and specialty preparations for specific indications. Mandatory outcome-registry participation.
In practice
A chronic-pain patient in Jersey who currently would face UK's two-treatment-failure barrier plus consultant-only prescribing could access appropriately-titrated medicinal cannabis from her GP under Jersey framework. A UK patient with fibromyalgia currently self-medicating illegally could access a proper prescription with clinician oversight via short travel — the same medicine, delivered legally, with proper dosing guidance and outcome tracking.
3b · Domestic vertical integration
Jersey's licensed cultivation base creates the option to build an end-to-end vertical from island-grown flower to patient-dispensed product without the supply-chain steps a UK or EU patient's prescription currently goes through.
Under UK / EU today
UK medicinal cannabis is imported (Canada, Netherlands, Denmark, Israel, and increasingly the licensed UK growers under Home Office cultivation licences). Cannabis-based medicinal products (CBMPs) prescribed on private prescription must be imported through Home Office-licensed importers, adding cost and delay. Product batch consistency across grow cycles and importers is patchy. There is no integrated cultivation-to-prescription pathway in the UK.
- When the same business grows, sells and effectively prescribes, there is a built-in financial conflict of interest.
- Product strength and contamination (pesticides, moulds, heavy metals) need independent testing.
- Risk of medical supply leaking into non-medical use.
- UN drug conventions require strict state control of cannabis cultivation.
What this means for Jersey. Keep ownership of cultivation separate from prescribing decisions, with independent product testing and full supply-chain records.
Under a Jersey framework
An end-to-end supply chain: island-grown flower, island-manufactured formulations (extracts, tinctures, capsules), dispensed through Jersey pharmacies — with prescribing kept independent. Prescribers hold no financial interest in growers or manufacturers, and every batch is independently tested for strength and contaminants. Traceability from patient prescription back to a specific grow cycle, with controls to prevent diversion to non-medical use.
In practice
A Jersey oncology patient could receive a specific full-spectrum THC:CBD formulation grown, manufactured and dispensed on the island — independently tested, and consistent from one prescription to the next.
3c · Extended therapeutic indications and research
The UK's licensed indication list is narrow (paediatric epilepsy, MS spasticity, some oncology nausea, chronic pain with strict criteria). Emerging evidence supports broader indications — anxiety, sleep disorders, autism spectrum management, some psychiatric applications — that the MHRA has not yet formally authorised.
Under UK / EU today
Off-label prescribing for emerging indications is technically possible but faces GMC scrutiny and often insurance-indemnity exclusions. Research on new indications requires MHRA CTA process (slow, expensive). Cultivator-to-clinical partnerships for indication research are structurally difficult given the split between Home Office cultivation licensing and MHRA clinical trial authorisation.
- For many proposed uses — anxiety, sleep, many chronic pain conditions — good-quality evidence is thin or mixed.
- Patients may use cannabis in place of treatments that are proven to work.
- Long-term risks are not well understood for many patient groups.
What this means for Jersey. New indications should be added only on the strength of evidence, ideally generated in Jersey’s own registered trials.
Under a Jersey framework
Extended indication list based on emerging evidence, updated on a defined review cycle. Research programmes coupling Jersey cultivators directly with clinical partners under a streamlined Jersey trial pathway (see Domain 05). Extended treatment programmes for chronic pain, anxiety, sleep, and oncology-adjacent conditions available in licensed, wellness-integrated clinical settings.
In practice
A patient with treatment-resistant chronic anxiety could access an authorised cannabis-medicine indication with proper clinician oversight — currently not available on the UK licensed formulary. A Jersey cultivator could run a small clinical trial of a novel full-spectrum formulation for sleep disorders under a Jersey trial authorisation, generating evidence that supports formulary expansion elsewhere.
- Devinsky O, et al. (2017). "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome." New England Journal of Medicine 376:2011-2020. doi.org/10.1056/NEJMoa1611618
- Whiting PF, et al. (2015). "Cannabinoids for Medical Use: A Systematic Review and Meta-analysis." JAMA 313:2456-2473. doi.org/10.1001/jama.2015.6358
- National Academies of Sciences, Engineering, and Medicine (2017). "The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research." doi.org/10.17226/24625
- Nugent SM, et al. (2017). "The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review." Annals of Internal Medicine 167:319-331. doi.org/10.7326/M17-0155
- UK medicinal cannabis market
- ~£100M in 2024, projected £600M by 2028 (Prohibition Partners, UK Cannabis Report 2024)
- European medicinal cannabis market
- €2B in 2024, projected €8-12B by 2028 (Prohibition Partners, European Cannabis Report 2024)
- Global medicinal cannabis market
- $16B in 2024, projected $46B by 2030 (Grand View Research, Legal Marijuana Market 2024)
- Jersey direct revenue at maturity
- £40-170M/year (revised: prescribing separated from growers; no supply for UK visitors to take home)
- Adjacent-industry multiplier
- £15-70M/year
- Total Jersey economic contribution — cannabis therapeutics
- £55-240M/year
What Jersey could offer in cannabis therapeutics
An integrated island supply chain: island-grown, island-formulated and island-dispensed, with independent batch testing and prescribing kept separate from growers' commercial interests. Fewer supply-chain steps between cultivation and patient than any UK or European equivalent, with a specialist-led prescriber pathway and broader formulary access than the UK where the evidence supports it.
Advanced therapeutics + longevity.
Longevity medicine is the emerging field aimed at slowing, arresting, or reversing the biological processes of ageing — not simply treating age-related diseases as they arise, but intervening earlier and more broadly to extend healthspan (the years of life lived in good health). It sits at the intersection of geroscience (the biological study of ageing), regenerative medicine (repairing or replacing damaged tissue), and precision therapeutics (personalised drug protocols).
The scientific case has moved substantially in the last decade. Interventions like caloric restriction, rapamycin, and metformin have shown consistent lifespan extension in animal models and — increasingly — early human evidence for healthspan extension. Recent human trials of senolytics (drugs that clear "senescent" cells that accumulate with age) have shown early efficacy in idiopathic pulmonary fibrosis and diabetic kidney disease. Anti-ageing peptides, low-dose GLP-1 agonists for metabolic health, and NAD+ precursors are all under active investigation.
4a · Peptides and GLP-1 receptor agonists
Peptides are short chains of amino acids (typically 2-50) that act as signalling molecules — instructions for the body to grow tissue, reduce inflammation, or repair specific systems. Research peptides such as BPC-157 (gut and connective tissue repair), thymosin alpha-1 (immune modulation), and epithalon (telomere biology) show consistent benefit in preclinical work.
GLP-1 receptor agonists (semaglutide, tirzepatide — brands Ozempic, Wegovy, Mounjaro, Zepbound) are the fastest-growing pharmaceutical category in history. Originally approved for type 2 diabetes, they proved dramatically effective for weight loss, and emerging evidence suggests cardiovascular, anti-inflammatory, and possibly longevity benefits well beyond glucose control.
Under UK / EU today
Research peptides (BPC-157, thymosin alpha-1, epithalon) are not licensed by the MHRA or EMA. There is no legal pharmacy supply chain. Patients wanting them buy from unregulated online research-chemical suppliers with no quality control, no sterility guarantee, and no dosing guidance. Prescribers who work with them face regulatory scrutiny. GLP-1s are MHRA-approved for type 2 diabetes and obesity within narrow BMI thresholds; NHS access is severely rationed. Private prescription is available but tight indication interpretation and off-label use for cardiovascular, anti-inflammatory or longevity indications carries prescriber indemnity risk.
- GLP-1 medicines are licensed for diabetes and obesity; outside those uses, stomach and bowel side effects, pancreatitis, gallbladder disease and muscle loss need weighing.
- European regulators have identified a very rare risk of a sudden eye condition (NAION) with semaglutide.
- Compounded and counterfeit versions have caused harm through dosing errors and poor quality.
- Peptides such as BPC-157 have no approved human use and very little human data; the FDA has flagged BPC-157 as a potential safety risk, and it is banned in sport.
- Many peptides sold online are “research grade”, with no guarantee of purity or sterility.
What this means for Jersey. GLP-1s can sit within a supervised framework. Peptides without human safety data should be research-only, not prescribed.
Under a Jersey framework
GLP-1s available under a broader metabolic-health indication framework, with mandatory patient-selection criteria (people of healthy weight seeking weight loss are ruled out), scheduled follow-up, monitoring for known side effects, and outcome tracking. Other peptides only where there is established human safety data, supplied as pharmaceutical-grade products through licensed pharmacies. Peptides without human safety data — including BPC-157 — are not prescribed; they are eligible only for registered research.
In practice
A patient with mild metabolic dysfunction (elevated fasting insulin, mild insulin resistance) could enter a supervised low-dose semaglutide protocol at a licensed Jersey clinic, with scheduled follow-up and monitoring. A patient asking for BPC-157 after an ACL reconstruction would not be prescribed it; at most they could join a registered study, because there is almost no human safety data.
4b · Rapamycin, senolytics, and geroprotectors
Rapamycin (also called sirolimus) is an FDA-approved immunosuppressant used for kidney transplant recipients. In low, intermittent doses it targets the mTOR pathway — a fundamental regulator of cellular growth and ageing — and shows consistent lifespan extension in animal studies.
Senolytics are drugs (dasatinib + quercetin combination; fisetin; navitoclax) that selectively kill senescent cells — cells that have stopped dividing but refuse to die, accumulating with age and driving chronic inflammation. Early human trials in specific age-related diseases have shown promise. Metformin, a decades-old diabetes drug, shows repeated observational signals of extended healthspan even in non-diabetic populations.
Under UK / EU today
Rapamycin is licensed as sirolimus for transplant immunosuppression only — a prescriber can technically write it off-label for longevity purposes, but doing so systematically carries MHRA scrutiny, indemnity risk, and no funded pathway. Long-term geroprotective studies are chronically underfunded because the patent expired decades ago and there is no commercial route to profit. Senolytic combinations (D+Q) are not licensed for any geroprotective indication — dasatinib is licensed for cancer only, quercetin sold as an unregulated supplement. Fisetin sold as a supplement with no dosing guidance. Metformin available on NHS prescription for type 2 diabetes only; off-label longevity prescribing exists in private practice but has no formal framework.
- There is no approved indication for “ageing”, so no regulator has a way to judge benefit; most longevity evidence comes from animals.
- Rapamycin suppresses the immune system — raising infection risk — and can cause mouth ulcers and raise blood sugar and cholesterol.
- Dasatinib, used in senolytic combinations, is a cancer drug with serious side effects; human senolytic trials are small and early.
- Metformin’s anti-ageing trial (TAME) has not reported, and metformin may blunt some benefits of exercise.
- Healthy people take on real risk for an unproven gain.
What this means for Jersey. Research only. These should be offered to healthy people only inside trials with proper consent and monitoring.
Under a Jersey framework
Research-led. Rapamycin, senolytics and metformin for healthy ageing offered only inside registered, ethics-approved trials, with defined dosing, patient selection, safety monitoring (blood counts, glucose, lipids and infection) and outcome registration. Dasatinib- and navitoclax-based senolytic protocols, which carry significant toxicity, restricted to trials with specialist haematology oversight. Where one of these drugs is used for its licensed purpose — metformin for diabetes, for example — normal prescribing applies.
In practice
A 45-year-old with elevated hs-CRP, a family history of Alzheimer's and mild cognitive concerns could enrol in a Jersey rapamycin trial with regular safety monitoring — rather than obtaining the drug off-label from a private clinician. The results would add to the evidence the field currently lacks.
4c · NAD+, klotho, exosomes, and stem cells
NAD+ is a critical coenzyme involved in cellular energy metabolism. Levels decline with age. IV NAD+ infusions and precursor supplements (NMN, NR) are widely used in longevity practice. Klotho is a longevity-associated protein under investigation as a therapeutic target. Exosome therapy uses cell-derived vesicles for tissue regeneration. Autologous stem-cell therapies use a patient's own cells (typically mesenchymal stem cells from adipose or bone marrow) for joint, soft-tissue, and aesthetic indications.
Under UK / EU today
NAD+ IV infusion is available privately in the UK but products are compounded from research-grade NAD sourced with variable quality; no MHRA approval as a therapeutic. Precursors (NR, NMN) sold as supplements with no quality assurance. Exosome therapy: FDA warning letters to US clinics; the UK operates under CE-mark medical-device rules with variable compliance, and clinics offering exosome therapy are effectively unregulated in practice. Autologous stem cells: caught by MHRA's Advanced Therapy Medicinal Product (ATMP) regulations, which require expensive centralised licensing that most clinics avoid — creating a grey market of unlicensed autologous stem-cell clinics with variable safety and no outcome tracking. Klotho: no approved therapeutic and no framework for early-access even for well-characterised studies.
- No exosome product is approved anywhere; the FDA has warned of serious infections and other harms from unapproved exosome treatments.
- Unproven stem-cell clinics have caused serious harm, including blindness, infections and tumours.
- There is no klotho therapy for humans — evidence is from animals only.
- NAD+ infusions have little evidence of benefit, and supplements sold as NAD+ precursors have no quality assurance.
- Leading stem-cell scientists warn against selling unproven interventions to patients.
What this means for Jersey. Research only. Nothing in this group has the evidence to be sold as treatment, and this is where reputational damage is most likely.
Under a Jersey framework
Research only. None of these has the evidence to be offered as treatment. Jersey could host registered trials — for example, autologous stem-cell (MSC) injections for knee osteoarthritis — with pharmaceutical manufacturing (GMP) standards, independent ethics review and long-term follow-up. NAD+ infusions, exosome products and klotho are not offered outside such trials.
In practice
A patient with chronic knee osteoarthritis could enrol in a registered trial of autologous MSC injection with proper manufacturing standards and long-term follow-up — rather than paying an unregulated clinic for an unproven procedure.
4d · Named-patient and compassionate-use supply
Compassionate use is the practice of authorising a specific patient to receive a medicine that has not yet completed regulatory approval — typically because the patient has an unmet clinical need and the therapeutic has strong evidence from early trials but is still years from full licensing.
Under UK / EU today
The UK operates the MHRA "specials" scheme (unlicensed medicines legal to prescribe when no licensed alternative exists — but limited to specific conditions, requires MHRA notification, and prescribers are cautious about the indemnity exposure) and the narrower named-patient supply route (individual patients with specific unmet need, manufacturer supply required, administratively cumbersome). EU jurisdictions operate similar but variable compassionate-use schemes under the Clinical Trials Regulation. Both frameworks were designed for the era before Phase 2 evidence commonly outran regulatory approval timelines and are poorly matched to today's pace of therapeutic development.
- Named-patient supply can be used to sidestep clinical trials rather than to meet a genuine unmet need.
- Side effects often go unrecorded, so nothing is learned from each use.
- Patients can end up paying for unproven drugs at a vulnerable moment.
What this means for Jersey. Keep it for genuine unmet need, with the treating doctor taking responsibility, mandatory adverse-event reporting and outcome registration.
Under a Jersey framework
A compassionate-use framework for pre-approval medicines with strong Phase 2 evidence that are not yet MHRA- or EMA-approved, for patients with a genuine unmet need. The treating doctor takes responsibility for each prescription; patients consent to registry participation as a condition of access; adverse events must be reported; outcomes go quarterly to a Jersey Health Innovation Framework Office. Applies to orphan-disease treatments and novel cancer medicines awaiting approval — not to longevity or lifestyle uses. Sits alongside, not instead of, the full approval pathway.
In practice
A rare-disease patient could access an antisense-oligonucleotide medicine that has shown strong Phase 2 results but is still years from EMA approval, with registry data contributing to approval elsewhere. A cancer patient who has exhausted approved options could access a novel medicine that recently completed Phase 2 with a strong signal.
- Harrison DE, et al. (2009). "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature 460:392-395. doi.org/10.1038/nature08221
- Justice JN, et al. (2019). "Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study." EBioMedicine 40:554-563. doi.org/10.1016/j.ebiom.2018.12.052
- Marso SP, et al. (2016). "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." New England Journal of Medicine 375:311-322. doi.org/10.1056/NEJMoa1603827
- Bannister CA, et al. (2014). "Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls." Diabetes, Obesity and Metabolism 16:1165-1173. doi.org/10.1111/dom.12354
- Hickson LJ, et al. (2019). "Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease." EBioMedicine 47:446-456. doi.org/10.1016/j.ebiom.2019.08.069
- Sikora KM, et al. (2021). "Cellular senescence in ageing, age-related disease and longevity." Nature Reviews Molecular Cell Biology 22:75-95. doi.org/10.1038/s41580-020-00314-w
- Global longevity + anti-ageing market
- $26.5B in 2023, projected $63.3B by 2030 (Grand View Research, Anti-aging Market 2024)
- Global peptide therapeutics
- $40B in 2023, projected $75B by 2030 (Fortune Business Insights, 2024)
- Global GLP-1 receptor agonists
- $50B in 2024, projected $150B by 2030 (Novo Nordisk + Eli Lilly earnings 2023-2024; JPMorgan Biotech Outlook 2024)
- Global regenerative medicine (stem cells, exosomes)
- $28B in 2024, projected $118B by 2030 (Precedence Research, 2024)
- Longevity-medicine clinics — global
- ~$10B in 2024, projected $44B by 2030 (McKinsey Wellness Report 2024)
- Jersey direct revenue at maturity
- £50-255M/year (revised: GLP-1 programmes and named-patient supply remain; rapamycin, senolytics, stem cells, exosomes, NAD+ and unapproved peptides move to research; includes £3-15M sponsor-funded research income)
- Adjacent-industry multiplier
- £20-100M/year
- Total Jersey economic contribution — longevity therapeutics
- £70-355M/year
What Jersey could offer in advanced therapeutics + longevity
A research-led advanced-therapeutics framework. Licensed medicines such as GLP-1s under physician supervision with outcome registration; unproven longevity interventions — rapamycin and senolytics for healthy ageing, stem cells, exosomes, NAD+ and unapproved peptides — only inside registered trials. This is not a wellness free-for-all — it is the opposite. The offer is regulatory clarity where the US has vacuum and the UK has silence, with mandatory data collection that turns use into evidence. Potentially the largest single revenue opportunity across the seven domains, though much of it depends on trials succeeding.
Clinical trial pathways.
Clinical trials are the structured process by which new medicines and treatments are tested in humans, generally moving through four phases: Phase 0 (micro-dose safety), Phase 1 (small-cohort safety), Phase 2 (efficacy signal in the target patient population), and Phase 3 (large randomised trials for regulatory approval). The regulatory framework governing trials — timelines to authorise, ethics review turnaround, protocol flexibility — is a major determinant of the cost and speed of bringing new medicines to patients.
The MHRA authorised n=1 personalised trials in principle (2023 Combined Ways of Working guidance) but the pathway is slow and administratively heavy. Adaptive trial designs, decentralised trials, and platform trials all fit uneasily within legacy Clinical Trial Authorisation (CTA) structures. Jersey could formalise faster, more flexible pathways for early-phase and personalised work — without abandoning safety oversight.
5a · n=1 personalised trials
Individual patients — typically with ultra-rare genetic conditions — receive bespoke therapeutics designed for their specific mutation. Milasen (developed for a single patient with Batten disease) established the template in 2018. The number of ultra-rare conditions where n=1 antisense-oligonucleotide, gene therapy, or peptide therapy is scientifically feasible is growing rapidly.
Under UK / EU today
The MHRA authorised n=1 personalised trials in principle in 2023 through its Combined Ways of Working guidance, but a full Clinical Trial Authorisation is still required for most cases. Ethics-committee review adds months; the regulatory-advisor plus trial-protocol drafting overhead is disproportionate to a single-patient trial. Each n=1 costs approximately £100-300k in regulatory + administrative overhead alone, before any therapeutic work. The EU Clinical Trials Regulation is slower still. The result: n=1 work in Europe happens in a handful of centres for a handful of patients per year despite scientific capacity for many more.
- With one patient, it is hard to tell whether the treatment worked or what would have happened anyway.
- Bespoke medicines are made fast and in small batches, so manufacturing quality and toxicity testing must not be cut.
- Families facing a fatal diagnosis may find it hard to weigh risks, which makes consent more difficult.
- Each case produces little evidence that helps other patients.
What this means for Jersey. Faster review is the goal, but the safety and manufacturing standards must be the same as for any trial.
Under a Jersey framework
A dedicated n=1 pathway with compressed IRB-equivalent ethics review (target 2-4 weeks), a single-patient CTA equivalent for defined categories (rare-disease antisense-oligonucleotide, rare-disease gene therapy, orphan-mutation peptide therapy), pre-approved protocol templates for the common variants, and mandatory outcome-registry participation as a condition of authorisation. Target regulatory overhead per n=1 trial: £20-50k versus the UK's £100-300k.
In practice
A UK family whose child has been diagnosed with an ultra-rare Batten-like mutation could commission a Milasen-style antisense-oligonucleotide therapeutic and have the trial authorised in Jersey in weeks not years. Platform n=1 models — currently forced through slower or more expensive pathways elsewhere — could run in a Jersey clinical-research unit under a dedicated n=1 authorisation.
5b · Phase 0 and micro-dosing studies
Ultra-early human pharmacokinetic and pharmacodynamic studies using sub-therapeutic doses — typically 1/100th of the expected pharmacologically active dose — to characterise how a drug moves through the body. Cheap and fast, useful for de-risking early-stage compounds before committing to a full Phase 1 investment.
Under UK / EU today
Phase 0 studies are permitted in principle but authorisation runs through the full Clinical Trial Authorisation pathway (typically 3-6 months) plus separate ethics review. The regulatory-administrative overhead dwarfs the actual study cost — a study that costs £50-150k to run generates £100-200k of regulatory expense. Result: most biotech either runs Phase 0 work outside the UK/EU (US, Australia, Netherlands) or skips it entirely and jumps to full Phase 1 with less de-risking information.
- Microdoses do not always predict how a drug behaves at a full dose.
- Participants get no health benefit, so even small risks need justifying.
- Some studies involve very small radiation doses.
What this means for Jersey. Low risk and widely accepted. Suitable for a faster Jersey pathway with standard ethics review.
Under a Jersey framework
A dedicated Phase 0 authorisation pathway. Compressed ethics review (target 2-3 weeks) recognising the ultra-low-risk nature of sub-pharmacological dosing. Simplified CTA-equivalent with pre-approved protocol templates for the common Phase 0 designs: PK characterisation, biomarker validation, target-engagement studies. Regulatory overhead scaled to actual study risk rather than legacy Phase 1 assumptions.
In practice
A biotech testing a novel small molecule could run a 6-subject microdose PK study in 8-12 weeks total from decision to result — currently 12-18 months in the UK. Multiple compounds could be de-risked in parallel in a single Jersey clinical-research unit; the winner advances to Phase 1 with confidence and higher probability of ultimate success.
5c · Adaptive and platform trials
Multi-arm, multi-stage trial designs allow trial structure to change based on interim results (adaptive) or test multiple treatments simultaneously against a shared control (platform). They answer more scientific questions per trial, use fewer patients, and are now standard practice in oncology and increasingly in other therapeutic areas.
Under UK / EU today
Permitted but treated case-by-case. Each adaptive design requires bespoke MHRA plus ethics negotiation; each novel platform structure requires full regulatory review from scratch. The statistical rigour is well understood but the regulatory review is slow. Large academic centres (MRC platform trials, some oncology cooperative groups) do run adaptive designs successfully — but access is limited to those with existing deep MHRA relationships. Smaller biotech and single-partner protocols face the full case-by-case burden.
- Changing a trial mid-way can make false-positive results more likely if the statistics are not planned carefully.
- Early looks at the data can bias how the trial is run.
- Needs independent data-monitoring committees and specialist statistical review.
What this means for Jersey. Accepted by the FDA and European regulators with safeguards. Jersey needs statistical expertise in its review office, not new rules.
Under a Jersey framework
Pre-approved adaptive-design and platform-trial templates for common use cases: dose-finding with adaptive randomisation, seamless Phase 1/2 designs, platform trials for defined therapeutic areas (rare disease, oncology, precision medicine). Fast-track authorisation for designs that fit existing templates. Bespoke authorisation for genuinely novel designs, with expedited turnaround (target 6-8 weeks vs UK's 4-6 months for novel designs).
In practice
A biotech running a rare-disease platform trial could add a novel-agent arm in weeks rather than the 6-9 month MHRA process. A precision-medicine dose-finding study for a novel therapeutic could use adaptive randomisation from Day 1 rather than fixed-cohort designs. Multiple compounds could share a single platform-trial infrastructure hosted on the island, reducing the per-compound trial cost significantly.
- Kim J, et al. (2019). "Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease." New England Journal of Medicine 381:1644-1652. doi.org/10.1056/NEJMoa1813279
- Bhatt DL, Mehta C (2016). "Adaptive Designs for Clinical Trials." New England Journal of Medicine 375:65-74. doi.org/10.1056/NEJMra1510061
- Woodcock J, LaVange LM (2017). "Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both." New England Journal of Medicine 377:62-70. doi.org/10.1056/NEJMra1510062
- Berry SM, et al. (2015). "The platform trial: an efficient strategy for evaluating multiple treatments." JAMA 313:1619-1620. doi.org/10.1001/jama.2015.2316
- Global clinical trials market
- $78B in 2024, projected $130B by 2030 (Grand View Research, Clinical Trials Market 2024)
- Global CRO (contract research organisation) market
- $85B in 2024, projected $163B by 2030 (Precedence Research, CRO Market 2024)
- Early-phase clinical trials segment
- ~$25B/year, growing at 6-7% CAGR
- Jersey direct revenue at maturity
- £10-40M/year (revised: niche work where speed and certainty matter more than cost — n=1 medicines, controlled-substance research, selected early-phase studies; Jersey will not compete on cost)
- Adjacent-industry multiplier
- £5-15M/year
- Total Jersey economic contribution — clinical trials
- £15-55M/year
What Jersey could offer in clinical trials
A properly-resourced regulatory office that can review protocols in weeks, not months, with the same safety bar as the UK and EU. Jersey will not compete on cost; the pitch is speed, certainty, and a published route from successful research to authorised treatment on the island. This is the most enabling piece of the whole framework — several other domains (psychedelics, longevity, novel diagnostics) depend on trial pathways being workable.
Advanced diagnostics.
Diagnostic technology has advanced far faster than the regulatory frameworks governing patient access to it. Whole-genome sequencing has fallen from $100 million per genome in 2003 to under $500 today. Full-body magnetic resonance imaging (MRI) can now screen an asymptomatic adult for hundreds of potential conditions in a single one-hour scan. Multi-cancer early detection (MCED) tests analyse a single blood sample for the DNA signatures of dozens of cancer types. Continuous glucose monitoring, once reserved for diabetics, is increasingly used by non-diabetic adults for metabolic optimisation.
Diagnostic-side regulation is generally lighter than therapeutic regulation, but access still varies enormously. UK access to these technologies is patchy — either NHS-triaged (reserved for symptomatic patients) or self-funded through private centres of variable quality. There is no single UK regulator setting standards for consumer-facing full-body MRI or MCED testing.
6a · Whole-genome sequencing + pharmacogenomics
A single blood or saliva sample can now be used to sequence a patient's complete genome (~3 billion base pairs) for under £500 at scale. The pharmacogenomic (PGx) subset — the ~200 genes that affect how a patient metabolises common medications — can predict which drugs will work well, which will need dose adjustment, and which will cause adverse effects.
Under UK / EU today
The NHS Genomics Medicine Service offers whole-genome sequencing only through defined disease-indication referrals (specific cancers, rare disease, some perinatal cases). There is no NHS route for asymptomatic-adult WGS. Private services (23andMe consumer tier, private clinics offering exome or WGS) exist but with variable quality, weak clinical follow-through, and PGx results rarely integrated into UK GP prescribing systems. The NHS is starting PGx testing at specific speciality prescribing points but broad access is not available.
- Tests often find “variants of uncertain significance”, which cause worry and unnecessary follow-up.
- Unexpected findings — for example a cancer risk gene — need genetic counselling that many providers do not offer.
- Genetic data raises privacy concerns and potential insurance implications.
- Pharmacogenomic evidence is strong for some drug–gene pairs and weak for others.
What this means for Jersey. Offer with genetic counselling, clear policies on unexpected findings, and PGx reporting limited to well-evidenced drug–gene pairs.
Under a Jersey framework
Authorised private-pay WGS + PGx pathway with quality-standard-approved providers, mandatory clinical follow-through built into every test order, and outcome-registry participation. Jersey-resident patients: PGx findings integrated into local pharmacy dispensing systems. International patients: standardised PGx summary transferred to home-country GP in NICE-guidance-compatible format. Standardised reporting format matching UK and EU frameworks so results are actionable everywhere the patient may receive care.
In practice
A patient could have full WGS + a comprehensive PGx panel run through an accredited Jersey clinic and laboratory to an external genomics lab, with results integrated into their longevity protocol within 4-6 weeks — including flags for any medications the PGx panel indicates need dose adjustment or substitution. Currently: this requires either US private labs (23andMe, Nucleus Genomics) with weak clinical follow-through, or the UK's tightly-triaged NHS Genomics pathway that most patients cannot access.
6b · Polygenic risk scores (PRS) for adults
Statistical models combining thousands of small-effect genetic variants to estimate a patient's genetic risk for common diseases: coronary artery disease, type 2 diabetes, breast cancer, prostate cancer, Alzheimer's disease. Score accuracy has improved dramatically over the last five years. Clinical use requires integration with family history, lifestyle factors, and clinician-guided interpretation.
Under UK / EU today
PRS is used in a handful of NHS research programmes (Genomics England pilots) and by two or three private providers with variable quality. No formal regulatory framework governs commercial PRS provision; scoring accuracy varies significantly between providers because of differences in reference-population data quality, variant selection, and score calibration. Clinical use is largely unstandardised — a PRS result from one provider is not directly comparable to another's, and integration with UK primary-care records is essentially absent.
- Polygenic risk scores predict individual risk only modestly.
- They are much less accurate for people of non-European ancestry.
- Clinical benefit — whether knowing your score improves health — has not been shown for most conditions.
- Can cause false reassurance or needless anxiety.
What this means for Jersey. Only alongside clinical risk factors and clinician interpretation — never as a standalone consumer result.
Under a Jersey framework
Authorised PRS-provider register with mandatory technical standards: score calculation transparency, population-baseline data quality requirements, uncertainty quantification, and per-disease validation. Mandatory clinician-guided interpretation as a condition of authorised delivery. Outcome-registry participation. Alignment with NICE family-history-assessment guidance so PRS sits inside a wider risk-management context rather than as standalone results.
In practice
A patient could receive a validated multi-disease PRS (cardiovascular disease, type 2 diabetes, several cancers, Alzheimer's) with clinician-guided interpretation integrating PRS + family history + lifestyle factors + biomarkers into a personalised risk-management plan and monitoring schedule. Currently: fragmented across multiple providers with variable quality, weak clinical integration, and no consistent framework for what to do with the results.
6c · Full-body MRI screening
US providers Prenuvo, Ezra, and Q Bio now offer one-hour full-body MRI scans for asymptomatic adults, screening for hundreds of potential conditions including early-stage cancers, aneurysms, and structural abnormalities. Cost is ~$2,500-3,500 per scan. The scan itself has minimal risk; the real challenge is managing the frequent incidental findings (things that look suspicious but usually aren't).
Under UK / EU today
No dedicated regulatory framework for consumer-facing full-body MRI. Private providers operate under general medical-imaging licensing that varies UK vs Ireland vs EU. The MHRA does not regulate scan interpretation quality. The GMC regulates individual radiologists but not the scan-service standard. Incidental-findings management is inconsistent across providers, generating both missed pathology and unnecessary follow-up cascades. UK availability is limited to a handful of private centres with quality varying significantly between them.
- The UK National Screening Committee and the Royal College of Radiologists do not support whole-body MRI for people without symptoms.
- Most scans find something; many findings are harmless but lead to anxiety, further scans and sometimes invasive biopsies.
- Risk of overdiagnosis — treating conditions that would never have caused harm.
- No evidence yet that it saves lives.
- Follow-up of findings falls on the public health service.
What this means for Jersey. Only with clear rules on what is reported, radiologist double-reading, agreed follow-up pathways paid for privately, and honest information on harms.
Under a Jersey framework
Authorised full-body MRI providers with quality-standard requirements: minimum scanner specification (typically 3T), protocol standardisation, mandatory dual-radiologist reporting for high-consequence findings, standardised incidental-findings management workflow (Reid criteria or equivalent), and outcome-registry participation tracking both findings and downstream follow-up outcomes. Positioned as the international quality-standard reference for private preventive imaging.
In practice
A patient could receive a Prenuvo-equivalent full-body MRI scan with Jersey-standard quality guarantees, dual-radiologist reporting, and clinician follow-through built into the pathway — with the scan interpreted and reviewed against the patient's baseline biomarker profile within 48 hours. Currently impossible in the UK except at variable-quality private centres where the scan is delivered but the framework for interpretation and follow-through is largely absent.
6d · Multi-cancer early detection (MCED) tests
Blood tests that detect cell-free DNA fragments released by tumours anywhere in the body — GRAIL's Galleri, Exact Sciences' Cancerguard, several others. A single blood draw can screen for signals of dozens of cancer types simultaneously, potentially detecting cancer 1-3 years earlier than symptomatic presentation.
Under UK / EU today
The NHS SYMPLIFY trial (2023) reported disappointing sensitivity in symptomatic patients, delaying wider NHS adoption of Galleri. GRAIL's Galleri is available privately in the UK at £999 per test with no formal framework for clinician follow-through of positive results — patients receive a result letter and are left to organise their own diagnostic follow-up. Test performance varies significantly by cancer type; the framework for false-positive management is largely absent, generating patient anxiety and unnecessary diagnostic cascades.
- Detects a small share of early-stage cancers — when treatment is most effective.
- False positives lead to anxiety and invasive investigations.
- No test has yet been shown to reduce cancer deaths.
- NHS England decided in 2024 not to start an early rollout of the Galleri test, pending final trial results.
What this means for Jersey. Offer only with counselling on what a result can and cannot tell you, fast-track follow-up for positives, and outcome tracking.
Under a Jersey framework
Authorised MCED-provider register (Galleri, Cancerguard, others) with mandatory pre-test counselling covering test limitations (per-cancer sensitivity, false-positive rate expectations), defined clinical follow-through pathways for positive results (imaging → specialist referral → definitive diagnosis, with time targets), standardised patient communication protocols, and mandatory outcome-registry participation. Registry data particularly important for MCED because population-level performance data is limited outside trials.
In practice
A patient could receive a Galleri-equivalent MCED test with a proper pre-test counselling conversation covering what the result will and will not tell them, a clear post-result pathway (positive → follow-up imaging plus specialist referral within days, not weeks; negative → routine surveillance integrated with their programme risk profile), and outcome tracking that feeds back into evolving best-practice for MCED use.
6e · Metabolic and physiological monitoring
DEXA body-composition scanning, VO2 max cardiopulmonary fitness testing, continuous glucose monitoring for non-diabetics, sleep-lab studies, HRV monitoring, and other physiological monitoring modalities have moved from athletic and clinical-only settings into consumer longevity programmes over the last five years.
Under UK / EU today
These modalities are lightly regulated as either consumer products or clinical products depending on route. Standardisation of protocols and interpretation is uneven; comparability between providers is poor. A DEXA scan at one clinic may not be directly comparable to a DEXA scan at another because of different scanner calibrations, positioning protocols, and reporting conventions. VO2 max testing similarly varies by protocol. CGM data for non-diabetics has no NHS interpretive framework at all.
- Glucose monitors in people without diabetes show normal fluctuations that are easily over-interpreted.
- Constant tracking can feed anxiety or disordered eating in some people.
- Consumer devices vary in accuracy.
What this means for Jersey. Low risk. Standardise measurement and give clinician interpretation rather than raw data.
Under a Jersey framework
Standardised protocol register for common metabolic/physiological modalities: DEXA body-composition (positioning, calibration, reporting), VO2 max cardiopulmonary testing (protocol standardisation, effort-verification), CGM interpretation for non-diabetics (glucose-variability metrics, meal-response scoring), sleep-lab studies for longevity indications. Quality-standard requirements plus standardised report formats that allow direct comparison over time and between providers.
In practice
A patient returning to Jersey for repeat assessments (annual, biennial) could directly compare their DEXA composition, VO2 max, CGM data, and sleep metrics across years with confidence that the measurements are truly comparable. This is currently impossible when different providers use different protocols and reporting standards — most longevity-programme patients have data from multiple providers that cannot be sensibly integrated.
- Nicholson BD, et al. (2023). "Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY)." Lancet Oncology 24:733-743. doi.org/10.1016/S1470-2045(23)00277-2
- Klein EA, et al. (2021). "Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set." Annals of Oncology 32:1167-1177. doi.org/10.1016/j.annonc.2021.05.806
- Swen JJ, et al. (2023). "A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study." Lancet 401:347-356. doi.org/10.1016/S0140-6736(22)01841-4
- Torkamani A, et al. (2018). "The personal and clinical utility of polygenic risk scores." Nature Reviews Genetics 19:581-590. doi.org/10.1038/s41576-018-0018-x
- Global consumer genomics market
- $2.5B in 2024, projected $10.4B by 2030 (Fortune Business Insights, 2024)
- Global full-body MRI + MCED market (combined)
- $5B in 2024, projected $18B by 2030 (Grand View Research + Kalorama Information 2024)
- Global longevity-diagnostics market
- $18B in 2024, projected $42B by 2030 (Grand View, Wellness Diagnostics Report 2024)
- Jersey direct revenue at maturity
- £85-340M/year (revised: full-body MRI and MCED offered only with stricter counselling, reporting and follow-up rules)
- Adjacent-industry multiplier
- £35-135M/year
- Total Jersey economic contribution — advanced diagnostics
- £120-475M/year
What Jersey could offer in advanced diagnostics
A single accredited regulator for advanced diagnostics: quality standards for scan interpretation, standardised reporting formats, mandatory secondary review for high-consequence findings, and outcome-registry participation. The US market has zero of this; the UK has patchwork. Jersey could set the international quality benchmark.
Aesthetic medicine.
Aesthetic medicine covers non-surgical treatments that improve appearance: injectable neurotoxins (Botox and similar), dermal fillers, radiofrequency and ultrasound skin-tightening, laser resurfacing, microneedling, thread lifts, and increasingly regenerative aesthetics using platelet-rich plasma and exosome-based skincare. It is one of the fastest-growing and least-well-regulated corners of medicine globally.
7a · Practitioner regulation and accreditation
Who is legally allowed to perform aesthetic procedures — inject fillers or toxins, run energy devices, perform threading, deliver medical microneedling — varies dramatically by jurisdiction. Injuries from unqualified practitioners are the single biggest source of aesthetic-medicine harm.
Under UK / EU today
The UK's aesthetic-practitioner regulation is notably weak: injectable procedures (Botox, dermal fillers) can be legally performed by non-clinicians — beauticians, dental hygienists, and self-taught practitioners with a weekend training course — in England and Wales. Save Face UK receives hundreds of harm complaints per year. Scotland is now moving toward licensing under the Regulation of Care Act; England and Wales have moved much slower. In the EU, regulation varies country-by-country with similar patchwork.
- The concern here is the absence of regulation: untrained injectors have caused blocked blood vessels, tissue death, blindness and infections.
- Poorly sourced products, including unlicensed botulinum toxin, have caused serious harm.
- The UK has been slow to introduce a licensing scheme.
What this means for Jersey. Tightening, not loosening — this is the kind of area where Jersey can lead safely.
Under a Jersey framework
Accredited-practitioner-only aesthetic register with mandatory clinical training (defined curriculum per procedure category), scope-of-practice restrictions matched to training level, mandatory continuing professional development, complaints and harms registry, and audit + enforcement machinery. Injectable procedures restricted to GMC-registered doctors, GDC-registered dentists, NMC-registered nurses with additional aesthetic training, and defined-scope aesthetic practitioners under supervision. Non-clinicians unable to perform invasive procedures.
In practice
A patient seeking aesthetic treatment in Jersey can be assured every injector, device operator, and skincare-medical practitioner on the island is on Jersey's aesthetic register with verified training. Complaints and harms flow to a functional registry, not just to Save Face and personal injury solicitors. The reputational risk of "aesthetics" as a category is contained by the framework rather than absorbed by individual providers.
7b · Device and procedure authorisation
New aesthetic devices and injectables typically arrive first in the US market via the FDA's 510(k) pathway (which permits new devices "substantially equivalent" to already-approved ones). They reach the UK years later, if at all, via CE-mark equivalence — often after the leading US practice has already moved to the next generation.
Under UK / EU today
New aesthetic devices and injectables must obtain UKCA marking (post-Brexit UK) or CE mark (EU) — pathways that are slower and administratively heavier than the FDA 510(k) equivalence route. UK availability of the latest aesthetic modalities typically lags US availability by 18-36 months. Some devices with strong FDA approval and demonstrated safety never come to the UK because the market opportunity does not justify the additional regulatory cost.
- Approval by “equivalence” to an existing device usually requires no new clinical trials, so new risks can be missed.
- Devices cleared this way in the US have later been recalled.
- Energy-based devices can cause burns, scarring and pigment changes if misused.
- UK and EU rules are slower precisely because they demand more safety evidence.
What this means for Jersey. Fast-track only with post-market surveillance, operator training requirements and the power to withdraw devices quickly.
Under a Jersey framework
Faster authorisation by equivalence, with safeguards. Devices with existing FDA clearance or CE/UKCA marking reviewed against equivalence evidence (typical target: 6-8 weeks) rather than requiring bespoke Jersey trials — but only with mandatory post-market surveillance and adverse-event reporting, operator-training requirements, and powers to suspend or withdraw a device quickly. Regenerative and exosome-based products are not eligible for this route (see 7c).
In practice
A next-generation RF microneedling device with FDA clearance could be available in a Jersey aesthetic clinic within weeks of authorisation — currently 18-36 months behind in the UK — with every adverse event reported and the device withdrawn quickly if problems emerge.
7c · Regenerative aesthetics (PRP, exosomes, novel biologics)
Regenerative aesthetics uses biological products — platelet-rich plasma from the patient's own blood, exosomes derived from stem cells, growth factors, and novel biologic formulations — to stimulate tissue regeneration rather than mask ageing effects. The field is growing quickly but sits awkwardly across cosmetic, medical-device, and biologic-therapeutic regulatory boundaries.
Under UK / EU today
Platelet-rich plasma (PRP) is legal but variably regulated depending on preparation route and provider claims. Exosome-based skincare products are sold with unclear regulatory status — some marketed as cosmetics (light regulation), some as medical devices (heavier regulation), and some in a grey area between. The MHRA has issued limited guidance. Novel biologic aesthetic products (peptide-based, growth-factor-based) typically enter the UK market through the cosmetic pathway with minimal oversight, or not at all.
- Exosome products are unapproved; the FDA has warned of contamination and serious infections.
- Poor infection control in unregulated “vampire facial” treatments led to HIV infections among clients of a US spa.
- Evidence that PRP and exosome treatments improve skin is limited and mixed.
- Product sourcing, sterility and characterisation are often unverified.
What this means for Jersey. PRP can be offered under strict infection-control and preparation standards. Exosomes and novel biologics should be research-only until products meet medicines standards.
Under a Jersey framework
PRP authorised under strict preparation and infection-control standards, with practitioner training and outcome registration. Exosome products and other novel biologics are not offered as treatment until they meet medicines standards; until then, research only.
In practice
A patient could receive PRP from an accredited practitioner using standardised, sterile preparation — avoiding the infection risks seen in unregulated settings. Exosome treatments would not be offered until products meet medicines standards.
- Alam M, et al. (2021). "The clinical utility of exosomes in dermatology and aesthetic medicine: a review." Journal of Cosmetic Dermatology 20:2467-2478. doi.org/10.1111/jocd.14203
- Small R (2014). "Botulinum toxin injection for facial wrinkles." American Family Physician 90:168-175. aafp.org (2014)
- Ozturk CN, et al. (2013). "Complications following injection of soft-tissue fillers." Aesthetic Surgery Journal 33:862-877. doi.org/10.1177/1090820X13493638
- Save Face UK (2024). "Annual Non-Surgical Cosmetic Complaints Report." Independent registry of UK aesthetic-medicine harm cases. saveface.co.uk
- Global aesthetic medicine market
- $65B in 2024, projected $110B by 2030 (Grand View Research, Medical Aesthetics Market 2024)
- UK non-surgical aesthetics
- ~£3.6B in 2024, growing 8-10% annually (Save Face UK industry estimates 2024)
- European non-surgical aesthetics
- ~€25B in 2024 (Grand View + IMCAS 2024)
- Jersey direct revenue at maturity
- £20-85M/year (revised: exosomes and novel biologics withdrawn; device fast-track kept with surveillance)
- Adjacent-industry multiplier
- £10-35M/year
- Total Jersey economic contribution — aesthetic medicine
- £30-120M/year
What Jersey could offer in aesthetic medicine
A properly-regulated aesthetic-practitioner framework — accredited-only practice, mandatory training, faster device authorisation by equivalence with post-market surveillance and withdrawal powers, and exosomes and novel biologics held to medicines standards. Positioned as the considered version of a currently under-regulated market.